Association of FOXP3 expression with non-small cell lung cancer

Anticancer Research

Volumn 31, Issue 5, 2011, Pages 1677-1683

  Dimitrakopoulos, Fotinos Ioannis D ^a   Papadaki, Helen ^a   Antonacopoulou, Anna G ^a   Kottorou, Anastasia ^a   Gotsis, Andreas D ^b   Scopa, Chrisoula ^a   Kalofonos, Haralabos P ^a   Mouzaki, Athanasia ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

FOXP3; Immunohistochemistry; Lung cancer; Lymph node; Metastasis; NSCLC

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADULT; AGE; AGED; ARTICLE; BRONCHUS MUCOSA; CANCER TISSUE; CELL LEVEL; CELL NUCLEUS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; T-LYMPHOCYTES, REGULATORY;

EID: 79958142099     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Miller YE: Pathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol 33(3): 216-223, 2005.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59(4): 225-249, 2009.
3. Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med 359(13): 1367-1380, 2008.
4. Sato M, Shames DS, Gazdar AF and Minna JD: A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2(4): 327-343, 2007. (Pubitemid 47181718)
5. Myatt SS and Lam EW: The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 7(11): 847-859, 2007. (Pubitemid 350006253)
6. Lal G and Bromberg JS: Epigenetic mechanisms of regulation of Foxp3 expression. Blood 114(18): 3727-3735, 2009.
7. Ebert LM, Tan BS, Browning J, Svobodova S, Russell SE, Kirkpatrick N, Gedye C, Moss D, Ng SP, MacGregor D, Davis ID, Cebon J and Chen W: The regulatory T-cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res 68(8): 3001-3009, 2008. (Pubitemid 351556301)
8. Chen GY, Chen C, Wang L, Chang X, Zheng P and Liu Y: Cutting edge: Broad expression of the FoxP3 locus in epithelial cells: a caution against early interpretation of fatal inflammatory diseases following in vivo depletion of FoxP3-expressing cells. J Immunol 180(8): 5163-5166, 2008.
9. Karanikas V, Speletas M, Zamanakou M, Kalala F, Louies G, Kerenidi T, Barda AK, Gourgoulianis KI and Germenis AE: Foxp3 expression in human cancer cells. J Transl Med 6: 19, 2008.
10. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grussel S, Sipos B, Grutzmann R, Pilarsky C, Ungefroren H, Saeger HD, Kloppel G, Kabelitz D and Kalthoff H: Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 67(17): 8344-8350, 2007. (Pubitemid 47395173)
11. Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, McNally B, Lin L, Zhou P, Zuo T, Cooney KA, Liu Y and Zheng P: Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 16(4): 336-346, 2009.
12. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, Liu Y, Wang Y, Liu X, Chan MW, Liu JQ, Love R, Liu CG, Godfrey V, Shen R, Huang TH, Yang T, Park BK, Wang CY, Zheng P and Liu Y: FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 129(7): 1275-1286, 2007. (Pubitemid 46970708)
13. Zuo T, Liu R, Zhang H, Chang X, Liu Y, Wang L, Zheng P and Liu Y: FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 117(12): 3765-3773, 2007. (Pubitemid 350224087)
14. Travis WD, World Health Organization, International Agency for Research on Cancer, International Association for the Study of Lung Cancer and International Academy of Pathology. Pathology and genetics of tumours of the lung, pleura, thymus, and heart. Lyon: IARC Press, 2004.
15. Taylor C: Quantifiable internal reference standards for immunohistochemistry: the measurement of quantity by weight. Appl Immunohistochem Mol Morphol 14(3): 253-259, 2006.
16. Ishibashi Y, Tanaka S, Tajima K, Yoshida T and Kuwano H: Expression of FOXP3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm. Oncol Rep 15(5): 1315-1319, 2006.
17. Fulop T, Kotb R, Fortin CF, Pawelec G, de Angelis F and Larbi A: Potential role of immunosenescence in cancer development. Ann NY Acad Sci 1197: 158-165, 2010.
18. Malaguarnera L, Cristaldi E and Malaguarnera M: The role of immunity in elderly cancer. Crit Rev Oncol Hematol 74(1): 40-60, 2010.
19. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, Tagliabue E and Balsari A: FOXP3 expression and overall survival in breast cancer. J Clin Oncol 27(11): 1746-1752, 2009.
20. Ciampa A, Xu B, Ayata G, Baiyee D, Wallace J, Wertheimer M, Edmiston K and Khan A: HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system. Appl Immunohistochem Mol Morphol 14(2): 132-137, 2006.
21. Brambilla E and Gazdar A: Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur Respir J 33(6): 1485-1497, 2009.
22. Zhu CQ, Blackhall FH, Pintilie M, Iyengar P, Liu N, Ho J, Chomiak T, Lau D, Winton T, Shepherd FA and Tsao MS: SKP2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with RAS mutation is a poor prognostic marker. Clin Cancer Res 10(6): 1984-1991, 2004.
23. Carrano AC, Eytan E, Hershko A and Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1(4): 193-199, 1999. (Pubitemid 129500937)
24. + T-regulatory cell activities in lung cancer. Cancer Res 65(12): 5211-5220, 2005. (Pubitemid 40827331)
25. + T-cells. J Immunol 175(3): 1483-1490, 2005.
26. Wang D and Dubois RN: Prostaglandins and cancer. Gut 55(1): 115-122, 2006. (Pubitemid 41820645)
27. Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, Kobayashi M, Satoh K, Narita M, Sugimoto Y, Murata T, Yoshimura H, Narumiya S and Majima M: Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 197(2): 221-232, 2003.
28. Mansfield AS, Heikkila PS, Vaara AT, von Smitten KA, Vakkila JM and Leidenius MH: Simultaneous FOXP3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer 9: 231, 2009.
29. Ohara M, Yamaguchi Y, Matsuura K, Murakami S, Arihiro K and Okada M: Possible involvement of regulatory T-cells in tumor onset and progression in primary breast cancer. Cancer Immunol Immunother 58(3): 441-447, 2009.
30. Beyer M and Schultze JL: Regulatory T-cells in cancer. Blood 108(3): 804-811, 2006.